Chemogenetic DREADD Therapeutics Market

How big is Chemogenetic DREADD Therapeutics Market in 2026?

With a valuation of USD 26.4 million in 2025 and moving to USD 31.0 million in 2026, the global chemogenetic DREADD therapeutics market is positioned to attain USD 156.8 million by 2036, exhibiting a CAGR of 17.6%.

PSAM4-GlyR chimeric receptors capture 54.8% of the engineered receptor platform segment in 2026 as the global chemogenetic DREADD therapeutics market advances from USD 26.4 million in 2025 and USD 31.0 million in 2026 toward USD 156.8 million by 2036 at a 17.6% CAGR. Hospital epilepsy centers and biopharma sponsors are buying packaged viral vectors and oral actuator ligands because one-third of focal seizure patients fail daily pills and need a reversible alternative to permanent brain-tissue surgery. On-demand neuronal silencing turns one-time viral infusions into controllable hospital treatments. Although pre-existing viral antibodies in adult patients still slow clinical screening, vector adoption is growing more than four times faster than antiepileptic drugs at a 4.3% CAGR. Clinical onboarding moved forward in April 2026 when the Second Affiliated Hospital of Zhejiang University registered Phase I trial NCT07533591 to evaluate stereotaxic AAV-hSyn-hM4Di gene therapy in patients [1]. Meanwhile, Voyager Therapeutics reported in May 2025 that its ALPL-binding VCAP-102 capsid boosted non-surgical brain gene transfer 20-fold to 400-fold in primates, widening systemic dosing options for neurology trial sponsors [2].

Key Market Trends & Insights

• By engineered receptor platform: PSAM4-GlyR Chimeric Receptors are expected to hold a 54.8% share in 2026, driven by humanized nicotinic-glycine chloride pores that silence neurons without G-protein delay.
• By actuator ligand: Ultra-Low-Dose Approved Agonists are estimated to command a 66.2% share in 2026, owing to repurposed oral drugs that bypass novel chemical entity toxicology filings.
• By therapeutic area: Focal Refractory Epilepsy is projected to account for a 51.6% share in 2026, attributable to localized stereotaxic AAV dosing directly into seizure foci.
• By viral delivery vector: BBB-Penetrant Engineered Capsids are predicted to record a 49.2% share in 2026, supported by transvascular brain gene transfer in primate and IND cohorts.
• By end user: Academic & Translational Centers are anticipated to garner a 46.5% share in 2026, reinforced by university hospital epilepsy and spinal-recovery vector cores.

Regional Highlights

• Top national expansion: Japan is projected to lead country growth at an 18.6% CAGR through 2036, enabled by QST primate deschloroclozapine PET imaging and corticospinal stroke recovery platforms.
• Broader country progression: Canada is forecast to expand at an 18.3% CAGR ahead of Germany at 18.1% and China at 17.8%, while the USA registers 17.5% and the UK reaches 17.0%.

Market Size & Forecast

Table 1: Market Size and Forecast for the Chemogenetic DREADD Therapeutics Market (USD million and CAGR percentage), 2025 to 2036

Metric	Value
2025 Market Size	USD 26.4 million
Estimated Market Size in 2026	USD 31.0 million
Projected Market Size by 2036	USD 156.8 million
CAGR, 2026 to 2036	17.6%
Added Revenue, 2026 to 2036	USD 125.8 million

Substitution of first-generation clozapine-N-oxide with selective, metabolically stable small-molecule actuators has become a core requirement for translational CNS gene-therapy sponsors across the USD 125.8 million growth window. Conventional clozapine-N-oxide shows poor brain entry and converts back into sedating clozapine, which clouds seizure and behavioral readouts during IND qualification. In January 2026, behavioral neuropharmacologists showed that while clozapine-N-oxide impairs spatial memory in mice lacking DREADD receptors, the synthetic agonist Compound 21 preserves cognitive performance [3]. Supported by cleaner actuator pharmacology, neuro-genetic teams are contracting with GMP adeno-associated virus packaging services to scale clinical DREADD and PSAM vector batches.

Viral-Vector Prep and Actuator-Ligand Batch Sizing

Table 2: Viral-Vector Prep and Actuator-Ligand Batch Sizing for the Chemogenetic DREADD Therapeutics Market (USD million and operational ranges), 2025 to 2036

Metric	2025	2026	2036
Market size (USD million)	26.4	31.0	156.8
Chemogenetic AAV/LV preps & plasmid lots shipped (thousand units)	14.5 to 17.2	16.8 to 20.0	72.0 to 86.0
Selective actuator ligand vials dispensed (thousand packs)	28.0 to 33.5	32.5 to 39.0	145.0 to 172.0
Translational & IND cohort valuation per program (USD thousand)	165.0 to 210.0	175.0 to 225.0	310.0 to 390.0

Operational note: Vector lot and ligand vial ranges align nonprofit plasmid repository distributions and specialty neuro-pharmacology catalog shipments with translational IND cohort budgets across focal epilepsy and neuropathic pain programs.

Selective cell-type promoters such as CaMKIIalpha and human synapsin restrict chemogenetic receptor expression to targeted excitatory pyramidal cells or dorsal-root pain neurons. Translational teams integrate chemogenetic circuit silencing into rare neurological disorder treatment pipelines so clinicians can adjust neuronal inhibition with oral micro-doses.

Per Capita & Neuro-Gene Therapy Center Sizing

Table 3: Per Capita and Neuro-Gene Therapy Center Spending Indicators for the Chemogenetic DREADD Therapeutics Market (USD), 2025 to 2036

Metric	2025	2026	2036
World population (billion)	8.2	8.3	9.0
Market value per 1,000,000 people (USD)	3,219.5	3,734.9	17,422.2
Annual valuation per active neuro-gene therapy center (USD thousand)	48.0 to 58.0	53.5 to 64.5	185.0 to 225.0
PSAM4-GlyR & FDA-approved ultra-low-dose agonist share (%)	53.5% to 65.0%	54.8% to 66.2%	58.0% to 69.5%

Table 4: Neuro-Gene Therapy Center and Actuator Ligand Spending Indicators for the Chemogenetic DREADD Therapeutics Market (USD and percentages), 2026

Metric	Value	Institutional Reference Basis
Market size, 2026	USD 31.0 million	2026 global chemogenetic valuation baseline
Active chemogenetic & CNS gene therapy labs	540 institutions	Global viral-vector & circuit neuroscience registry
PSAM4-GlyR chimeric receptor allocation, 2026	USD 17.0 million	54.8% engineered receptor platform share
Ultra-low-dose approved agonist allocation, 2026	USD 20.5 million	66.2% actuator ligand share

Clinical trial sponsors combine positron-emission tomography radioligands such as carbon-11 deschloroclozapine with video-EEG telemetry to verify transgene expression in vivo before oral agonist dosing. Non-invasive receptor occupancy verification speeds up neurology clinical trial execution across academic medical centers.

Analyst Perspective

"Moving chemogenetics from rodent circuit mapping into human epilepsy and chronic pain clinics requires pairing non-immunogenic chimeric ion channels with already approved ultra-low-dose oral ligands. Developers that combine blood-brain-barrier-penetrant AAV capsids with sub-milligram varenicline or deschloroclozapine dosing will lead clinical commercialization through 2036."

- Anurag Sharma, Principal Consultant, Future Market Insights.

How is the chemogenetic DREADD therapeutics market segmented?

The chemogenetic DREADD therapeutics market is segmented across five core axes covering engineered receptor platform and actuator ligand as well as therapeutic area, viral delivery vector, and end user. In 2026, PSAM4-GlyR Chimeric Receptors is projected at 54.8% and Ultra-Low-Dose Approved Agonists at 66.2%. Focal Refractory Epilepsy holds 51.6% and BBB-Penetrant Engineered Capsids record 49.2%, while Academic & Translational Centers account for 46.5%.

By engineered receptor platform: PSAM4-GlyR Chimeric Receptors and Inhibitory hM4Di & KORD as well as Excitatory hM3Dq & GsD and Peripheral & Enteric DREADDs.

By actuator ligand: Ultra-Low-Dose Approved Agonists, Deschloroclozapine (DCZ), and Compound 21 & uPSEM817.

By therapeutic area: Focal Refractory Epilepsy, Intractable Neuropathic Pain, and Stroke & Spinal Recovery.

By viral delivery vector: BBB-Penetrant Engineered Capsids and Stereotaxic AAV8 & AAV9 as well as Cell-Specific Enhancer AAVs and Lentiviral & Non-Viral Vectors.

By end user: Academic & Translational Centers and Biopharma R&D Sponsors as well as Neurosurgical Epilepsy Clinics, Contract Research Organizations, and Nonprofit Vector Repositories.

Why do PSAM4-GlyR Chimeric Receptors lead the engineered receptor platform category?

PSAM4-GlyR Chimeric Receptors are expected to hold a 54.8% share in 2026, driven by humanized ion-pore architecture and direct chloride shunting.

Table 5: Engineered Receptor Platform Share for the Chemogenetic DREADD Therapeutics Market (percentage share), 2026

Product Type	Share (2026)
PSAM4-GlyR Chimeric Receptors	54.8%
Other Segments Combined*	45.2%
Total	100.0%

*Calculated as the balance remaining after deducting the leading segment's reported share from 100.0%.

Table 6: Engineered Receptor Platform Leadership and Market Growth for the Chemogenetic DREADD Therapeutics Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	17.6%
Leading Segment	PSAM4-GlyR Chimeric Receptors

PSAM4-GlyR splices a mutated human alpha-7 nicotinic acetylcholine binding domain onto a human glycine receptor chloride pore, forming an ion channel that shunts depolarizing sodium currents upon agonist binding. Whereas muscarinic GPCR DREADDs depend on intracellular G-protein cascades that can desensitize over repeated dosing, chimeric ion channels give direct membrane conductance control across neurodegenerative disease therapy pipelines.

• PSAM4-GlyR Chimeric Receptors are expected to hold a 54.8% share in 2026, driven by humanized sequence homology and rapid neuronal silencing.
• In March 2025, epilepsy gene-therapy investigators at Lund University reported in Gene Therapy that AAV-delivered PSAM4-GlyR activated by uPSEM792 or varenicline suppressed epileptiform discharges across epileptic hippocampus models [4].

Why do Ultra-Low-Dose Approved Agonists define the largest actuator ligand segment?

Ultra-Low-Dose Approved Agonists are estimated to hold a 66.2% share in 2026, owing to established human safety and pharmacokinetic dossiers.

First-generation clozapine-N-oxide suffers from weak blood-brain barrier entry and metabolic back-conversion into sedating clozapine. Dosing FDA-approved varenicline for PSAM4-GlyR or ultra-low-dose olanzapine for mutated muscarinic receptors at nanomolar plasma levels lets investigators use licensed oral tablets during cell and gene therapy clinical trials.

• Ultra-Low-Dose Approved Agonists are estimated to hold a 66.2% share in 2026, owing to pre-cleared human pharmacokinetics and reliable oral bioavailability.
• In December 2025, Lund University epilepsy researchers noted in the Journal of Internal Medicine that pairing synthetic ligand-gated ion channels with clinically approved small-molecule activators removes CNO back-metabolism risks in human translation [5].

What keeps Focal Refractory Epilepsy ahead in the therapeutic area category?

Focal Refractory Epilepsy is projected to account for a 51.6% share in 2026, attributable to localized hippocampal AAV dosing.

Mesial temporal lobe epilepsy with hippocampal sclerosis starts inside a defined unilateral seizure focus that neurosurgeons can transduce with microliter stereotaxic AAV infusions without altering whole-brain cognition. Patients then take a fast-acting oral actuator capsule only when aura symptoms or EEG signals warn of an oncoming seizure, placing chemogenetics at the front of in vivo CNS disorder gene therapies.

• Focal Refractory Epilepsy is projected to account for a 51.6% share in 2026, attributable to clear surgical target boundaries and high unmet drug-resistant patient demand.
• In April 2025, medicinal chemists at Harbin Medical University published a study in Frontiers in Cellular Neuroscience introducing a humanized Gs-coupled DREADD cloned from Addgene plasmid 213972 to expand human-compatible chemogenetic signaling [6].

Why do BBB-Penetrant Engineered Capsids lead the viral delivery vector category?

BBB-Penetrant Engineered Capsids are predicted to record a 49.2% share in 2026, supported by non-surgical transvascular CNS delivery.

RNA-directed AAV capsid evolution platforms identify capsid variants that bind blood-brain barrier receptors such as alkaline phosphatase (ALPL) to cross into the brain after a simple intravenous infusion. Transvascular delivery avoids invasive craniotomy for multifocal cortical and spinal pain circuits while integrating with viral vector manufacturing workflows.

• BBB-Penetrant Engineered Capsids are predicted to record a 49.2% share in 2026, supported by broad cortical and spinal cord transduction in non-human primates.
• In February 2026, University of Colorado Boulder and Yale neuroscientists reported in The Journal of Neuroscience that multiweek chemogenetic DREADD inhibition of caudal granular insular cortex projections produced an enduring reversal of neuropathic pain [7].

What gives Academic & Translational Centers the leading position in end user?

Academic & Translational Centers are anticipated to garner a 46.5% share in 2026, reinforced by NIH and AMED circuit-mapping and IND grants.

University medical centers and national neuroscience institutes purchase the largest annual volume of ready-to-use AAV-DREADD viral preps, enhancer-AAV toolkits, and water-soluble actuator ligands. Academic vector cores validate cell-type-specific promoters in human resected brain slices before licensing clinical candidates to biopharma sponsors.

• Academic & Translational Centers are anticipated to garner a 46.5% share in 2026, reinforced by multi-center epilepsy and spinal-cord recovery grants.
• In December 2025, Harvard Medical School pain researchers reported in Pain that DREADD-based chemogenetic activation of visual cortex astrocytes triggered CGRP-dependent meningeal nociception and migraine-like pain behaviors [8].

What are the drivers, restraints, and opportunities in the chemogenetic DREADD therapeutics market?

Across the chemogenetic DREADD therapeutics market, reversible oral-ligand seizure silencing and spinal circuit recovery propel vector and agonist demand, whereas neutralizing AAV antibodies restrain continuous dosing and BBB-penetrant capsids unlock systemic indications.

• Driver: Reversible, patient-titrated oral ligand activation gives neurosurgeons a controllable safety switch over permanent gene overexpression or tissue ablation.
• Restraint: Prolonged GPCR agonist exposure can arrest glial homeostasis or downregulate receptors, while neutralizing AAV antibodies exclude seropositive patients.
• Opportunity: Excitatory hM3Dq and inhibitory PSAM4-GlyR circuit remodeling after ischemic stroke and spinal cord injury opens large neuro-rehabilitation markets.

Growth Analysis and Future Potential: Qualitative Demand Catalysts

Unlike constitutive potassium-channel or neuropeptide gene therapies that permanently alter baseline neuronal firing, chemogenetics stays silent until the patient takes a micro-dose of the selective actuator ligand. Reversible pharmacology lets clinicians calm hyperexcitable hippocampal CA2 pyramidal cells during seizure clusters while preserving normal memory and pairing with neurological biomarker monitoring. In January 2026, psychiatric neuroscientists at the Nathan Kline Institute and Columbia University demonstrated in Neurobiology of Disease that selective chemogenetic modulation of hippocampal area CA2 pyramidal cells governs acute and chronic seizure generation in temporal lobe epilepsy mice [9]. Neurosurgical epilepsy teams are therefore prioritizing inducible chemogenetic cassettes that can be adjusted or paused if off-target sedation appears.

Risk Assessment of the Chemogenetic DREADD Therapeutics Market: Operational and Formulation Friction

Continuous high-dose DREADD agonist administration over several days can trigger beta-arrestin receptor internalization or disrupt microglial signaling inside injured brain tissue. In addition, 30% to 60% of adult patients carry pre-existing neutralizing antibodies against wild-type AAV8 and AAV9 capsids, requiring plasmapheresis or capsid engineering paired with precision gene editing tools. In a January 2025 Mayo Clinic study published in Brain Behavior and Immunity, researchers showed that acute Gi-DREADD activation reduced kainic-acid seizure severity whereas repeated three-day CNO dosing arrested microglia in a low-activity state that increased neuronal loss [10]. Translational protocols therefore favor intermittent, on-demand ultra-low-dose agonists over continuous receptor saturation.

Commercial Opportunity Analysis: Formulation Differentiation and Value-Add Formats

Neuro-rehabilitation represents a major growth avenue as investigators use excitatory hM3Dq and inhibitory PSAM4-GlyR vectors to rewire spared corticospinal tracts after stroke or spinal cord trauma. Targeted chemogenetic interneuron modulation paired with custom viral vector development platforms speeds up forelimb and walking recovery during physical therapy windows. In July 2025, neurosurgical teams at Wuhan University and Duke University Medical Center reported in Brain Stimulation that chemogenetic hM3Dq activation in peri-infarct and contralateral motor cortex circuits boosted post-stroke neuroplasticity and motor recovery [11]. Suppliers offering ready-to-inject spinal and cortical AAV-DREADD kits paired with water-soluble deschloroclozapine dihydrochloride are capturing neuro-regeneration grant budgets.

Chemogenetic DREADD Therapeutics Market by Country (2026 to 2036)

According to FMI country modeling, Japan is projected to lead national chemogenetic DREADD therapeutics growth at an 18.6% CAGR between 2026 and 2036, followed by Canada at 18.3% and Germany at 18.1%.

Table 7: Country CAGR and Primary Growth Levers for the Chemogenetic DREADD Therapeutics Market (CAGR percentage and operational drivers), 2026 to 2036

Country	CAGR (2026 to 2036)	Primary Growth Lever
Japan	18.6%	QST/AMED primate deschloroclozapine (DCZ) chemogenetics and corticospinal stroke recovery platforms
Canada	18.3%	Spinal cord injury circuit-reconstruction cohorts and CIHR-funded AAV9 chemogenetic neuroregeneration
Germany	18.1%	Helmholtz and university hospital focal epilepsy AAV-DREADD and patch-clamp validation networks
China	17.8%	First-in-human Phase I stereotaxic AAV-hM4Di clinical trials and CNS gene-therapy hospital consortia
USA	17.5%	Voyager TRACER BBB-penetrant capsids, Addgene viral vector repository, and NIH HEAL pain programs
UK	17.0%	UCL Queen Square genetic epilepsy trials and Hello Bio / Tocris chemogenetic actuator manufacturing
France	16.8%	Paris Brain Institute and INSERM translational epilepsy and basal-ganglia circuit modulation
Australia	16.4%	MRFF neuro-epilepsy gene therapy consortia and cortical pain-circuit chemogenetic validation

Source: Future Market Insights analysis

Japan Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Investigators in Japan at the National Institutes for Quantum Science and Technology (QST) invented deschloroclozapine (DCZ) and carbon-11 DCZ PET imaging, making Japan the primary hub for non-human primate chemogenetics. In June 2026, researchers at Niigata University and Kyoto University reported in Nature Communications that AAV-Syn-FLEX-PSAM4-GlyR chemogenetic silencing in the cervical spinal cord proved secretogranin II-driven corticospinal-V2a interneuron rewiring governs post-stroke motor recovery [12]. High GMP viral-vector import fees still encourage domestic CDMO packaging partnerships across Tokyo and Kobe. Supported by AMED primate connectomics and PMDA Sakigake regenerative medicine pathways, demand for chemogenetic DREADD therapeutics in Japan is projected to expand at an 18.6% CAGR through 2036.

Key takeaway: In Japan, deschloroclozapine PET-guided primate chemogenetics and post-stroke PSAM4-GlyR motor recovery studies are projected to drive an 18.6% CAGR.

Canada Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Spinal cord injury and epilepsy research institutes in Winnipeg and Toronto as well as Montreal and Vancouver rely on Cre-dependent AAV9 vectors and selective chemogenetic actuators to rebuild damaged neural pathways across Canada. Between 2026 and 2036, the chemogenetic DREADD therapeutics market in Canada is forecast to expand at an 18.3% CAGR, supported by federal health research grants and translational neuro-regeneration consortia. In July 2025, spinal cord neuroscientists at the University of Manitoba reported in The Journal of Neuroscience that combining Addgene-sourced AAV9-CamKII-GFP-Cre and AAV9-hSyn-eGFP-Cre transneuronal tracing with receptor neuromodulation restored synaptic connectivity after traumatic spinal cord injury [13]. Cross-border dry-ice shipping fees for high-titer viral vectors still pressure academic lab budgets across Canada.

Key takeaway: In Canada, CIHR-funded spinal cord circuit reconstruction programs and epilepsy surgery centers are forecast to sustain an 18.3% CAGR through 2036.

Germany Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Neurology departments in Bonn and Berlin as well as Munich and Freiburg combine human resected epileptic tissue slice electrophysiology with AAV-transduced chemogenetic validation before clinical trial entry. Across Germany, the chemogenetic DREADD therapeutics market is anticipated to rise at an 18.1% CAGR between 2026 and 2036 across university hospital viral-vector core facilities and neurosurgical epilepsy clinics. Whereas uniQure's Phase I/IIa AMT-260 program uses constitutive AAV9 microRNA silencing of endogenous GRIK2/GluK2 kainate receptors [14], translational teams in Germany focus on inducible PSAM4-GlyR and hM4Di vectors that allow reversible oral agonist titration in refractory patients. Strict Paul-Ehrlich-Institut advanced therapy medicinal product release testing governs clinical vector batch certification across German academic centers.

Key takeaway: In Germany, human hippocampal slice validation and Paul-Ehrlich-Institut ATMP trial pathways are anticipated to support an 18.1% CAGR through 2036.

China Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Neurosurgical hospitals in Hangzhou, Beijing, and Wuhan are moving stereotaxic AAV-hM4Di and enteric Gi-DREADD constructs directly into translational primate and human clinical studies. Demand for chemogenetic DREADD therapeutics in China is predicted to climb at a 17.8% CAGR from 2026 to 2036, propelled by domestic GMP viral-vector biomanufacturing and municipal brain-science grants across major metropolitan medical centers. In April 2025, gastroenterology and neural-circuit investigators reported in Cellular and Molecular Gastroenterology and Hepatology that deschloroclozapine-driven Gi-DREADD activation selectively modulates enteric and central neural pathways at nanomolar doses [15]. Hospital ethics boards in China still require multi-month carbon-11 PET biodistribution tracking before approving multi-center stereotaxic patient dosing across neurology departments.

Key takeaway: In China, Phase I neurosurgical AAV-hM4Di trials and domestic viral-vector biomanufacturing are predicted to deliver a 17.8% CAGR through 2036.

USA Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Anchored by Addgene's viral repository in Massachusetts and Voyager Therapeutics' TRACER capsid discovery platform as well as NIH HEAL non-opioid pain consortia, the USA represents the largest national buyer of chemogenetic vectors and selective agonists. Valuation for chemogenetic DREADD therapeutics in the USA is projected to grow at a 17.5% CAGR between 2026 and 2036 across IND-enabling refractory epilepsy and neuropathic pain programs. In May 2026, University of Michigan neuroscientists demonstrated in Frontiers in Cellular Neuroscience that clozapine-N-oxide impairs spatial memory independent of DREADDs whereas selective Compound 21 preserves cognitive performance [16]. FDA combination-product potency assays for paired viral vectors and small-molecule actuators require dedicated CDMO analytical validation.

Key takeaway: In the USA, NIH HEAL pain programs and domestic BBB-penetrant AAV capsid licensing are projected to sustain a 17.5% CAGR through 2036.

UK Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Bristol-based chemogenetic ligand manufacturers Tocris Bioscience and Hello Bio and genetic epilepsy research groups at the UCL Queen Square Institute of Neurology anchor demand in the UK. Sales of chemogenetic DREADD therapeutics in the UK are estimated to expand at a 17.0% CAGR through 2036 under MHRA Innovative Licensing and Access Pathway incentives for neurological gene therapies. In February 2025, neurosurgery and rehabilitation investigators demonstrated in Neurotherapeutics that acute-phase chemogenetic AAV5-hSyn-hM3Dq injection combined with low-dose clozapine sped up locomotor recovery and axonal regeneration after spinal cord injury [17]. Tight NHS specialized commissioning budgets still require clear cost-effectiveness evidence against resective temporal lobectomy across UK hospital trusts.

Key takeaway: In the UK, Bristol high-purity DREADD agonist production and UCL genetic epilepsy trials are estimated to drive a 17.0% CAGR through 2036.

France Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Translational neuroscience teams in France at the Paris Brain Institute (ICM) and INSERM deploy hM3Dq and hM4Di vectors to map basal ganglia and cortical seizure networks. In August 2025, a translational review in JOR Spine detailed how chemogenetic DREADD modulation of lumbar central pattern generators and serotonergic pathways restores rhythmic walking after severe spinal cord injury [18]. Market value for chemogenetic DREADD therapeutics in France is forecast to advance at a 16.8% CAGR through 2036, supported by France 2030 biotherapy and viral-vector biomanufacturing grants across Paris and Lyon. ANSM genetically modified organism containment reviews for hospital stereotaxic suites remain the main procedural hurdle in France.

Key takeaway: In France, INSERM and Paris Brain Institute circuit-mapping programs funded by France 2030 biotherapy grants are forecast to support a 16.8% CAGR.

Australia Chemogenetic DREADD Therapeutics Market Outlook (2026 to 2036)

Melbourne and Sydney epilepsy and pain research institutes are adopting water-soluble deschloroclozapine and enhancer-AAV vectors to study cortical pain circuits and drug-resistant genetic epilepsies. Between 2026 and 2036, the chemogenetic DREADD therapeutics market in Australia is expected to grow at a 16.4% CAGR, supported by Medical Research Future Fund neuro-translation grants and Therapeutic Goods Administration clinical trial notifications. Hello Bio's technical dossier for water-soluble Deschloroclozapine dihydrochloride (HB9126) documents over 99% purity and 100-fold higher hM3Dq/hM4Di affinity than CNO across international cortical pain and epilepsy laboratories [19]. Cold-chain air freight for imported AAV viral preps still adds lead time for Australian university and hospital neuroscience laboratories.

Key takeaway: In Australia, MRFF epilepsy and cortical pain research programs are expected to sustain a 16.4% CAGR through 2036.

Full report country CAGRs cover: North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa.

Who are the notable companies in the chemogenetic DREADD therapeutics market?

Codon / Magnus Neurosciences, Zhejiang University Neuro-AAV Consortia, Voyager Therapeutics, Inc., Addgene, Bio-Techne Corporation (Tocris Bioscience), Hello Bio Ltd., Cayman Chemical Company, and Charles River Laboratories are the notable companies in the chemogenetic DREADD therapeutics market.

FMI analysis indicates that the chemogenetic DREADD therapeutics ecosystem connects translational PSAM and DREADD receptor developers with blood-brain-barrier AAV capsid pioneers and high-purity actuator ligand manufacturers. Suppliers compete on AAV serotype packaging titers and transvascular brain penetration as well as zero-clozapine-impurity synthesis of water-soluble deschloroclozapine, uPSEM817, and Compound 21.

• Translational PSAM & Neuro-AAV Chemogenetic Developers: Codon / Magnus Neurosciences and Zhejiang University Neuro-AAV Consortia advance chimeric ion-channel neuromodulation and Phase I stereotaxic AAV-hM4Di gene therapy cohorts.
• Blood-Brain-Barrier-Penetrant AAV Capsid & Vector Repositories: Voyager Therapeutics and Addgene along with Charles River Laboratories provide transvascular CNS capsids, ready-to-use enhancer-AAV chemogenetic preps, and GMP viral packaging.
• Specialty Chemogenetic Agonist & GMP Small-Molecule Formulators: Bio-Techne Corporation (Tocris Bioscience) and Hello Bio Ltd. along with Cayman Chemical Company synthesize water-soluble deschloroclozapine (DCZ), uPSEM792/817, and Compound 21.

Competitive Benchmarking: Chemogenetic DREADD Therapeutics Market

Table 8: Competitive Benchmarking for the Chemogenetic DREADD Therapeutics Market (qualitative capability ratings), 2026

Company	Receptor & AAV Vector Depth	Actuator Ligand Purity	Clinical & Translational Reach	Geographic Reach
Codon / Magnus Neurosciences	High	High	High	Medium
Zhejiang University Neuro-AAV Consortia	High	Medium	High	High
Voyager Therapeutics, Inc.	High	Medium	High	High
Addgene	High	Medium	High	High
Bio-Techne Corporation (Tocris Bioscience)	Medium	High	High	High
Hello Bio Ltd.	Medium	High	High	High
Cayman Chemical Company	Medium	High	High	High
Charles River Laboratories	High	Medium	High	High

Scoring basis: Capability tiers assess validated AAV serotype packaging titers above 1e13 vg/mL and blood-brain-barrier transcytosis efficiency as well as >=99% HPLC purity of water-soluble DREADD and PSAM agonists with zero parent clozapine contamination.

Key Developments in the Chemogenetic DREADD Therapeutics Market

• In July 2025, structural pharmacologists published cryo-EM design data for a peripherally restricted Gi-DREADD (HCAD) that selectively silences dorsal-root ganglion pain neurons without crossing the blood-brain barrier [20].
• In May 2025, Addgene expanded its enhancer-AAV toolbox and ready-to-use chemogenetic AAV viral repository to enable cell-type-specific neuronal circuit manipulation [21].
• In October 2025, QST investigators in Japan published longitudinal carbon-11 deschloroclozapine PET imaging benchmarks in eLife confirming stable AAV-hM4Di and AAV-hM3Dq expression in non-human primate brains over 150 days [22].

Key Players in the Chemogenetic DREADD Therapeutics Market

Translational PSAM & Neuro-AAV Gene Therapy Developers

• Codon / Magnus Neurosciences
• Zhejiang University Neuro-AAV Consortia
• Voyager Therapeutics, Inc.

Viral Vector Repositories & CNS Biomanufacturing Platforms

• Addgene
• Charles River Laboratories
• Bio-Techne Corporation (Tocris Bioscience)

Specialty Chemogenetic Agonist & GMP Small-Molecule Formulators

• Hello Bio Ltd.
• Cayman Chemical Company

Chemogenetic DREADD Therapeutics Market - Report Scope

Table 9: Report Scope for the Chemogenetic DREADD Therapeutics Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Engineered Receptor Platform; Actuator Ligand; Therapeutic Area; Viral Delivery Vector; End User
Quantitative Units	USD Million
Market Definition	Includes commercial supplier, licensing, and translational R&D contract revenue from engineered chemogenetic receptor vectors (PSAM4-GlyR, PSAM-5HT3, hM3Dq, hM4Di, KORD, GsD), BBB-penetrant AAV chemogenetic capsids, and selective actuator ligands (ultra-low-dose varenicline/olanzapine, deschloroclozapine, uPSEM817/792, Compound 21). Excludes constitutive non-chemogenetic AAV9 microRNA gene silencing therapies (such as uniQure's AMT-260 GRIK2/GluK2 knockdown), conventional high-dose oral antiepileptic drugs, and fiber-tethered optogenetic laser systems.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	Japan, Canada, Germany, China, USA, UK, France, Australia, and additional countries in the full report
Key Companies Covered	Codon / Magnus Neurosciences, Zhejiang University Neuro-AAV Consortia, Voyager Therapeutics, Inc., Addgene, Bio-Techne Corporation (Tocris Bioscience), Hello Bio Ltd., Cayman Chemical Company, Charles River Laboratories
Forecast Period	2026 to 2036
Approach	Primary and secondary research with top-down and bottom-up market triangulation.

Chemogenetic DREADD Therapeutics Market - Research Methodology

Table 10: Research Methodology for the Chemogenetic DREADD Therapeutics Market (research methods and approach), 2026 edition

Method	Approach
Primary Research	Structured interviews with epilepsy gene therapy investigators and AAV capsid protein engineers as well as neuro-pharmacology medicinal chemists and viral repository directors.
Secondary Research	Analysis of peer-reviewed chemogenetic studies in Gene Therapy, Molecular Therapy, Nature Communications, and The Journal of Neuroscience in addition to ClinicalTrials.gov registry records (NCT07533591).
Market Sizing and Forecasting	Top-down CNS gene therapy and translational neuromodulation R&D budgets reconciled against bottom-up AAV chemogenetic vector lot shipments and selective actuator ligand sales from 2026 to 2036.
Country Forecasting Model	Country growth rates weight drug-resistant focal epilepsy surgical waitlists and national viral-vector biomanufacturing capacity across eight evaluated countries.
Operational Benchmark Traceability	Viral-vector prep and actuator-ligand sizing indicators in Tables 2, 3, and 4 cross-check against Lund University PSAM4-GlyR epilepsy cohorts and Voyager ALPL capsid studies.
Data Triangulation and Validation	Segment shares and revenue projections are audited across all five parent axes to verify 100.0% share summation without double counting standard psychiatric antipsychotics.

Chemogenetic DREADD Therapeutics Market by Segments

Chemogenetic DREADD Therapeutics Market segmented by Engineered Receptor Platform:

• PSAM4-GlyR Chimeric Receptors
• Inhibitory hM4Di & KORD
• Excitatory hM3Dq & GsD
• Peripheral & Enteric DREADDs

Chemogenetic DREADD Therapeutics Market segmented by Actuator Ligand:

• Ultra-Low-Dose Approved Agonists
• Deschloroclozapine (DCZ)
• Compound 21 & uPSEM817

Chemogenetic DREADD Therapeutics Market segmented by Therapeutic Area:

• Focal Refractory Epilepsy
• Intractable Neuropathic Pain
• Stroke & Spinal Recovery

Chemogenetic DREADD Therapeutics Market segmented by Viral Delivery Vector:

• BBB-Penetrant Engineered Capsids
• Stereotaxic AAV8 & AAV9
• Cell-Specific Enhancer AAVs
• Lentiviral & Non-Viral Vectors

Chemogenetic DREADD Therapeutics Market segmented by End User:

• Academic & Translational Centers
• Biopharma R&D Sponsors
• Neurosurgical Epilepsy Clinics
• Contract Research Organizations
• Nonprofit Vector Repositories

Chemogenetic DREADD Therapeutics Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] Second Affiliated Hospital, Zhejiang University School of Medicine / U.S. National Library of Medicine. (2026, April 24). Study Details | NCT07533591 | Clinical Study of Chemogenetic Gene Therapy With AAV for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus (STP-001 AAV-hSyn-hM4Di). ClinicalTrials.gov.
• [2] Voyager Therapeutics, Inc. (2025, May 15). Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication. Voyager Therapeutics Investor Relations.
• [3] Bunce, B., VanKampen, A. A., He, A., Aton, S. J., & Raven, F. (2026, January 12). DREADD agonist Clozapine-N-oxide, but not Compound 21, impairs spatial memory in non-DREADD expressing mice. Preprint / PMC Open Access (PubMed Central PMC12871256).
• [4] Gonzalez-Ramos, A., Berglind, F., Kudlacek, J., Rocha, E. R., Melin, E., Sebastiao, A. M., Valente, C. A., Ledri, M., Andersson, M., & Kokaia, M. (2025, March 01). Chemogenetics with PSAM4-GlyR decreases excitability and epileptiform activity in epileptic hippocampus. Gene Therapy, 32(2), 106-120 (PubMed Central PMC11946892 / PMID 39455855).
• [5] Ledri, M., & Kokaia, M. (2025, December 09). Gene therapy for epilepsy: An emerging, promising approach for a serious neurological disorder. Journal of Internal Medicine, 299(3), 302-327 (PubMed Central PMC12869011).
• [6] Zhang, Q., Wang, R., Zhang, L., Li, M., Lin, J., Lu, X., Tian, Y., Lin, Y., Liu, T., Chen, Y., Li, Y., Cao, J., Wu, Q., Wang, J., Lu, Z., & Hong, Z. (2025, April 09). A humanized Gs-coupled DREADD for circuit and behavior modulation. Frontiers in Cellular Neuroscience, 19, 1577117 (PubMed Central PMC12015759).
• [7] Ball, J. B., Finch, M. R., Taylor, J. A., Smith, Z. Z., Rocha, I. R. C., Green-Fulgham, S. M., Rowe, E. B., Dragavon, J. M., McNulty, C. J., Dreher, R. A., Siddique, I. I., Davis, G., Tan, A. M., Baratta, M. V., Barth, D. S., & Watkins, L. R. (2026, February 04). Caudal Granular Insular Cortex to Somatosensory Cortex I: A Critical Pathway for the Transition of Acute to Chronic Pain. The Journal of Neuroscience, 46(5), e1306252025 (PubMed PMID 41402127).
• [8] Bree, D., Zhao, J., Stratton, J., & Levy, D. (2025, December 01). Cortical astrocyte activation triggers meningeal nociception and migraine-like pain. Pain, 166(12), e758-e769 (PubMed PMID 40728530).
• [9] LaFrancois, J. J., Kennedy, M., Rathod, M., Santoro, B., Lisgaras, C. P., Siegelbaum, S. A., & Scharfman, H. E. (2026, January 03). Chemogenetic activation of hippocampal area CA2 promotes acute and chronic seizures in a mouse model of epilepsy. Neurobiology of Disease, 107256 (PubMed PMID 41490873).
• [10] Dheer, A., Bosco, D. B., Zheng, J., Wang, L., Zhao, S., Haruwaka, K., Yi, M.-H., Barath, A., Tian, D.-S., & Wu, L.-J. (2025, January 01). Chemogenetic approaches reveal dual functions of microglia in seizures. Brain, Behavior, and Immunity, 115, 406-418 (PubMed Central PMC10841657).
• [11] Yu, X., Jian, Z., Dang, L., Zhang, X., He, P., Xiong, X., Feng, Y., & Rehman, A. U. (2025, July 15). Chemogenetic modulation in stroke recovery: A promising stroke therapy approach. Brain Stimulation, 18(4), 1028-1036 (PubMed PMID 40340020).
• [12] Sato, T., Nakamura, Y., Hoshina, K., Inoue, K., Takada, M., Yano, M., Matsuzawa, H., & Ueno, M. (2026, June 09). Scg2 drives corticospinal circuit reorganization with spinal premotor interneurons and astrocytes for motor recovery after stroke in mice. Nature Communications, 17, 4880 (PubMed Central PMC13249867).
• [13] Hosseini, S. M., Stecina, K., Nemati, S., Wang, R. R., Zhang, J. V., & Karimi-Abdolrezaee, S. (2025, July 31). Circuit Reconstruction after Traumatic Spinal Cord Injury by Cellular and Pharmacological Approaches. The Journal of Neuroscience, 45(35), e0362252025 (PubMed Central PMC12392074).
• [14] uniQure N.V. (2026, June 19). Phase I/IIa Clinical Trial of AMT-260 | Programs & Pipeline | uniQure (AAV9 microRNA Silencing of GRIK2/GluK2 Kainate Receptors in Refractory MTLE; Non-Chemogenetic Comparator). uniQure N.V.
• [15] Chen, X., et al. (2025, April 14). DREADDs-Based Chemogenetics Induced Slow Transit Driven by Deschloroclozapine (DCZ) Selectively Modulates Enteric and Central Neural Circuits. Cellular and Molecular Gastroenterology and Hepatology (PubMed Central PMC12038534 / PMID 40223443).
• [16] Bunce, B., VanKampen, A. A., He, A., Aton, S. J., & Raven, F. (2026, May 08). Clozapine-N-oxide impairs spatial memory independent of DREADDs. Frontiers in Cellular Neuroscience, 20, 1785079 (PubMed Central PMC13194068 / PMID 42179846).
• [17] Kim, J. H., Hwang, S. Y., Lee, H.-L., Yoon, S. L., Ha, Y., Lee, H. Y., & Ryu, S. (2025, February 14). Effects of chemogenetic virus injection and clozapine administration in spinal cord injury. Neurotherapeutics, 22(2), e00547 (PubMed Central PMC12014403).
• [18] Su, H., Jing, L., Lv, D., Huan, Z., & Xu, W. (2025, August 11). Central Pattern Generators in Spinal Cord Injury: Mechanisms, Modulation, and Therapeutic Strategies for Motor Recovery. JOR Spine, 8(3), e70100 (PubMed Central PMC12338084).
• [19] Hello Bio Ltd. (2026, January 15). Deschloroclozapine dihydrochloride (DCZ) (water soluble) (HB9126) Technical & Biological Data. Hello Bio Chemogenetics Catalog.
• [20] Kang, H. J., et al. (2025, July 10). Structure-guided design of a peripherally restricted chemogenetic system for dorsal root ganglion pain modulation. Cell / PMC Open Access (PubMed Central PMC12291529).
• [21] Addgene. (2025, May 21). An enhancer-AAV toolbox to target and manipulate distinct neuronal populations with ready-to-use chemogenetic AAV preparations. Addgene Scientific Repository.
• [22] Nagai, Y., Miyakawa, N., Takuwa, H., Hori, Y., Oyama, K., Ji, B., Takahashi, M., Huang, X.-P., Slocum, S. T., DiBerto, J. F., Xiong, Y., Urushihata, T., Hirabayashi, T., Fujimoto, A., Mimura, K., English, J. G., Liu, J., Inoue, K.-I., Kumata, K., & Minamimoto, T. (2025, October 22). Longitudinal assessment of DREADD expression and efficacy in the nonhuman primate brain using [11C]deschloroclozapine PET. eLife (PubMed PMID 41123579 / PMC12543322).
• [23] Huang, Z., et al. (2025). Hippocampal Inhibitory Interneuron-Specific DREADDs Treatment Alters mTORC1-4E-BP Signaling and Impairs Memory Formation.. Journal of neurochemistry, 169(3), e70048 (PMC11931476).

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the chemogenetic DREADD therapeutics market in 2026 and what is forecast for 2036?
• Which clinical and neuro-genetic catalysts accelerate adoption of chemogenetic DREADD therapeutics?
• Why do PSAM4-GlyR Chimeric Receptors lead the engineered receptor platform category?
• Why do Ultra-Low-Dose Approved Agonists lead the actuator ligand category?
• How do national growth rates compare between Japan and Canada versus Germany, China, and the USA?
• Which companies lead AAV chemogenetic vector design, BBB-penetrant capsids, and selective actuator ligand synthesis?
• What biological and immunological hurdles restrain continuous dosing in the chemogenetic DREADD therapeutics market?
• What specifications should translational teams verify when selecting chemogenetic viral vectors and small-molecule actuators?